Extended Data Fig. 10: LNP-mediated synthetic antigen treatment augments antitumor immunity in a preclinical model of heterogenous glioblastoma tumors. | Nature Cancer

Extended Data Fig. 10: LNP-mediated synthetic antigen treatment augments antitumor immunity in a preclinical model of heterogenous glioblastoma tumors.

From: Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens

Extended Data Fig. 10

(a) EGFRvIII- (vIII-) or EGFRvIII+ (vIII+) SB28 tumor cells were transfected with 100 ng of VHH-LNP and evaluated for VHH expression by flow cytometry after 18 hrs, mean of n = 5 technical replicates from a single experiment (b) Mice bearing a heterogenous tumor mixture comprised of 90% vIII- and 10% vIII+ SB28 tumor cells were treated with saline or VHH-LNP followed by adoptive transfer of indicated CAR T cells (c) 24 hrs following intratumoral injection VHH-LNP (5 µg), SB28 tumors were dissociated and analyzed by flow cytometry for EGFRvIII (left) and VHH (right) expression, one-way unpaired T test, mean ± s.d., n = 3 dissociated tumors, each from individual mice; ***p = 0.0008, n.s.=nonsignficiant. (d) Representative flow plots of VHH expression on SB28 tumors treated with either saline or VHH-LNP. Data is representative of 3 tumors each isolated from one mouse (e) Tumor growth curves of heterogenous SB28 tumor-bearing mice treated with intratumorally with saline or VHH-LNP and systemically with either WT, αVHH, or αEGFRvIII CAR T cells days indicated days by dashed lines (D0, D7, & D14) n = 5 untreated and VHH-LNP + αVHH CAR treated mice, n = 6 mice with αEGFRvIII CAR T cell treatment, n = 7 mice with VHH-LNP + saline treatment. (f) Survival curves from (e) of heterogenous SB28 tumor-bearing mice following synthetic antigen treatment, log-rank (Mantel–Cox) test; **p = 0.0019 comparing EGFRvIII CAR treatment with LNP + αVHH CAR.

Source data

Back to article page